Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

Affiliations

• ¹ Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France. karim.fizazi@gustaveroussy.fr.
• ² Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
• ³ National Cancer Center Hospital East, Chiba, Japan.
• ⁴ Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
• ⁵ PUCRS School of Medicine, Porto Alegre, Brazil.
• ⁶ IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Italy.
• ⁷ National Cancer Center, Goyang, Republic of Korea.
• ⁸ Auckland City Hospital, Auckland, New Zealand.
• ⁹ University of Auckland, Auckland, New Zealand.
• ¹⁰ Clinique Victor Hugo Centre Jean Bernard, Le Mans, France.
• ¹¹ School of Cancer Sciences, University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK.
• ¹² Carolina Urologic Research Center, Myrtle Beach, SC, USA.
• ¹³ Arizona Urology Specialists, Tucson, AZ, USA.
• ¹⁴ National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany.
• ¹⁵ Akershus University Hospital (Ahus), Lørenskog, Norway.
• ¹⁶ Fudan University Shanghai Cancer Center, Shanghai, China.
• ¹⁷ Pfizer Inc., La Jolla, CA, USA.
• ¹⁸ Pfizer Inc., Collegeville, PA, USA.
• ¹⁹ Pfizer Inc., Durham, NC, USA.
• ²⁰ Pfizer Inc., New York, NY, USA.
• ²¹ Huntsman Cancer Institute (NCI-CCC), University of Utah, Salt Lake City, UT, USA. neeraj.agarwal@hci.utah.edu.